SAN ANTONIO BUSINESS JOURNAL
http://www.bizjournals.com/
GenSpera preparing anti-cancer drug compound for Phase II study
San Antonio Business Journal by James Aldridge,
Date: Thursday, March 29, 2012, 10:14am CDT
Detailed information about buy generic viagra the disorder This is for all those men who suffer from erection dysfunction and weakness. cheapest brand cialis Striking it may impact the whole body, that takes a long time to come in the medical prescription. The problems have arisen over time with the misuse of the medication, and other is the side effects of reducing the amount cheapest online cialis of insulin. Also known as sildenafil medicines, india cheapest tadalafil they work well for most men across the world. GenSpera Inc. has completed the dose-escalation component of the company’s Phase I trial of its lead chemotherapeutic agent, G-202.
The trial will continue in up to 18 additional patients in order to further refine the dosing regimen and determine a recommended dose for Phase II clinical studies. The Phase I trial currently is being conducted at the University of Wisconsin Carbone Cancer Center in Madison; the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore and the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio The University of Texas Health Science Center at San Antonio Latest from The Business Journals Follow this company in San Antonio.
San Antonio-based GenSpera (OTCBB: GNSZ) is a development stage oncology company. GenSpera is working to perfect a technology platform that has the ability to deliver thapsigargin, a plant-derived cytotoxin, only within the tumor. The company’s platform is based on nine U.S. patents.
For more information, visit this link.
Local business press coverage counts. For a lot. This piece about GenSpera’s continuing clinical trial helps raise the company’s profile among investors, potential partners and in the San Antonio biotech community, which is gaining a national reputation.